

RESEARCH ARTICLE

FAHR SYNDROME REVEALED BY A CONVULSIVE CRISIS ASSOCIATED WITH IATROGENIC HYPERPARATHYROIDISM: CASE REPORT

Najoua Benothman, Fadoua Elkayla, Manal Rhezali and Taoufik Abouelhassan Reception Service And Vital Emergencies, CHU Med VI of Marrakech Morocco.

Manuscript Info	Abstract
•••••	
Manuscript History	Fahr's syndrome is a rare anatomoclinical entity whose main etiology is
Received: 10 February 2023	primary or postoperative hypoparathyroidism. It is characterized by
Final Accepted: 14 March 2023	bilateral and symmetrical intracerebral calcifications, localized in the
Published: April 2023	basal ganglia. Hypoparathyroidism, primary or postoperative, is the
	most classic anomaly. Hyperparathyroidism is exceptionally reported
Key words	as a cause of Fahr syndrome. We report the case of a 30-year-old
Inaugural Tonic Clonic Seizure, Fahr Syndrome, Calcifications,	woman who presented with an inaugural convulsive seizure revealing
Hyperparathyroidism	Fahr's syndrome secondary to iatrogenic hyperparathyroidism.

Copy Right, IJAR, 2023,. All rights reserved.

Introduction:-

Fahr's syndrome is a rare anatomo-clinical entity, characterized by bilateral and symmetrical intracerebral calcifications, localized in the central gray nuclei, most often associated with calcium phosphate metabolism disorders. We report the case of a 30-year-old patient who presented with an inaugural convulsive seizure revealing Fahr's syndrome with hyperparathyroidism.

Patient and Observation:-

This is a 30-year-old patient, anemic for 3 years, thyroidectomized in 2011 for nodular goiter under LT4 100ug complicated by iatrogenic hyperparathyroidism under Unalpha 0.25ug per day and calcium 2 to 3 g per day without any notion of discontinuation of treatment. Admitted to shock for unique and inaugural generalized tonic clonic crisis with post-critical confusion. A cerebral CT scan was performed, showing bilateral and symmetrical calcifications of the central gray nuclei (Figure 1), subsequently benefiting from a cerebral MRI objectifying a bilateral signal anomaly and symmetrical, related to calcifications revealing fahr syndrome of metabolic origin

The phosphocalcic balance, marked by severe hypocalcemia at 51 mg/l (VN: 86-100). The complete blood count objectifying an emia at 7.6g/dl, the blood ionogram, the liver test, the kidney test and the hemoglobin A1c were normal. The diagnosis of Fahr Syndrome was retained and a substitution treatment with Unalpha and calcivitamin D was started in association with neuropsychiatric treatment. The evolution was marked by the correction of phosphocalcic metabolism disorders.

Discussion:-

Fahr syndrome (FS) is defined by the presence of cerebral, non-arteriosclerotic, bilateral and symmetrical calcifications affecting the basal ganglia. It is a rare condition, characterized by clinical polymorphism with a predominance of neuropsychiatric manifestations and phosphocalcic metabolism disorders. FS occurs preferentially in patients with dysparathyroidism, mainly hypoparathyroidism [1-2-3].

Hypoparathyroidism is the most common cause of FS-related hypocalcemia. Hypocalcaemia caused by hypoparathyroidism explains the majority of clinical signs (cataract, malabsorption, neuromuscular hyperexcitability, various neurological and neuropsychic signs, psychiatric disorders that can go as far as psychosis, various cardiovascular disorders). [4-5]

Pseudohypoparathyroidism is a familial condition defined by peripheral resistance to parathyroid hormone. On the biological level, we then find hypocalcemia, hyperphosphatemia, but a serum level of normal or high parathyroid hormone. Hyperparathyroidism is exceptionally reported as a cause of FS [6-7].

The analysis of the literature made it possible to collect less than ten observations of hyperparathyroidism during this syndrome [8-9].

Other causes give intracerebral calcifications such as endocrinopathies, system diseases, celiac disease, infections, primary or secondary calcified brain tumors and other various diseases, however, during these different pathologies, calcifications intracerebral cells have different locations and aspects [10].

The prognosis of Fahr's syndrome is good, because the clinical and neuropsychic signs regress after correction of the phosphocalcic disturbances [6].

Conclusion:-

FS is a rare neurological disease, creating a contrast between severe non-specific symptomatology and a simple and effective treatment. The correction of phosphocalcic metabolism disorders allows a marked improvement in clinical symptoms, hence the interest of systematically looking for these disorders in the face of any neuropsychiatric manifestation associated with calcifications of the central gray nuclei.

Competing interests

The authors declare no competing interest.

Authors' contributions

All authors listed are contributors to this article

Figures




Figure 1:- Axial CT scans illustrating images of dense, symmetrical and bilateral calcification in the central gray nuclei.

References:-

1. Fahr T. Idiopathische Verkalkung der Hirngefässe. Zentralbl Allg Pathol. 1930-1931; 50:129-33.

2. Fatima El Boukhrissi, Ghizlane Zoulati, Issam En-nafaa. Fahr syndrome secondary to primary hypoparathyroidism: about a case. Pan African Medical Journal. 2017; 26:2

3. El Hechmi, Bouhlel S, Melki W, El Hechmi Z. Psychotic disorder secondary to Fahr syndrome: about a case. Brain. 2014 Jun; 40(3): 271-5.

4. Rharrabti S, Darouich I, Benbrahim M, Belahsen F, Rammou I, Alouane R et al. Confusional syndrome revealing Fahr syndrome with hyperparathyroidism. Pan Afr Med J. 2013 Mar 29; 14:123.

5. Otheman Y, Khalloufi H, Benhima I, Ouanass A. Neuropsychiatric manifestations revealing pseudohypoparathyroidism with Farh syndrome.Brain. 2011 Feb; 37(1): 54-8

6. Ceccaldi B, el Maghraoui A, Mayaudon H, Dupuy O, Eulry F, Bauduceau B. Fahr syndrome and hyperparathyroidism.Med Press. 1999 Apr 3; 28(13):689.

7. Younes-Mhenni S, Tobois S, Streichenberger N, et al. Melas-type mitochondrial encephalomyopathy associated with Fahr syndrome with cerebellar calcifications. Internal Rev Med. 2002 Dec; 23(12):1027-9.

8. Khadir K, Moussaid L, el Oazzani T, Gam I, Slassi I, Azzouzi S, et al. Fahr syndrome secondary to dermatologically revealed hypoparathyroidism. Ann Dermatol Venereol. 2004 Nov;131(11):979-83.

9. Sbai H, Smail L, Hamdani S, Essatara Y, Harrandou M et al. Fahr syndrome discovered following pneumococcal meningitis. Internal Rev Med. 2008 May; 29(5):412-4.

10. Souad Rharrabti, Ilhame Darouich, Mohamed Benbrahim.Confusional syndrome revealing Fahr syndrome with hyperparathyroidism.Pan African Medical Journal. 2013; 14:123.